References
- Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723–35.
- Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al.. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117–27.
- Verstovsek S, Mesa R, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al.. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). J Clin Oncol. 2011;299:Abstract 6500.
- Harrison CN, Kiladijan JJ, Al-Ali HK, Gisslinger H, Waltzman RJ, Stalbovskaya V, et al.. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol. 2011;29:Abstract LBA6501.
- Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Levy R, et al.. Durable Responses with the JAK1/JAK2 Inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood. 2010;116:Abstract 313.
- Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al.. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29:789–96.
- Pardanani A, Caramazza D, George G, Lasho TL, Hogan WJ, Litzow MR, et al.. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol. 2011;29:Abstract 6514.
- Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, et al.. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27:4563–9.
- Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, et al.. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011;25(2):301–4.
- Guglielmelli P, Barosi G, Rambaldi A, Marchioli A, Masciulli L, Tozzi F, et al.. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011;118:2069–76.